Cv Sciences, Inc. (CVSI) — 8-K Filings

8-K Filings (14)

• CV Sciences Enters Material Definitive Agreement — Oct 10, 2025 Risk: medium
  CV Sciences, Inc. filed an 8-K on October 10, 2025, reporting on an event that occurred on October 7, 2025. The filing indicates the entry into a Material Defin
• CV Sciences Enters Material Definitive Agreement — Sep 18, 2025 Risk: medium
  CV Sciences, Inc. entered into a Material Definitive Agreement on February 12, 2025. The company, formerly known as CannaVEST Corp. and Foreclosure Solutions, I
• CV Sciences Files 8-K on Financials — Aug 13, 2025 Risk: low
  CV Sciences, Inc. filed an 8-K on August 13, 2025, reporting on its Results of Operations and Financial Condition as of March 27, 2025. The filing also includes
• CV Sciences Files 8-K on Shareholder Votes and Financials — Jun 5, 2025 Risk: low
  CV Sciences, Inc. filed an 8-K on June 5, 2025, reporting on matters submitted to a vote of security holders and financial statements as of March 27, 2025. The
• CV Sciences Enters Material Definitive Agreement — Feb 20, 2025 Risk: medium
  CV Sciences, Inc. announced on February 12, 2025, that it entered into a material definitive agreement. The filing also includes financial statements and exhibi
• CV Sciences Files 8-K Under 'Other Events' — Feb 19, 2025 Risk: low
  CV Sciences, Inc. filed an 8-K on February 19, 2025, reporting an event that occurred on February 12, 2025. The filing is categorized under 'Other Events' and d
• CV Sciences Terminates Material Definitive Agreement — Feb 11, 2025 Risk: medium
  CV Sciences, Inc. filed an 8-K on February 11, 2025, to report the termination of a material definitive agreement that occurred on February 5, 2025. The filing
• CV Sciences Acquires Plus Products for $16.5M — Nov 25, 2024 Risk: medium
  CV Sciences, Inc. announced on November 20, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Plus Pro
• CV Sciences Files 8-K: Material Agreement & Equity Sales — Nov 21, 2024 Risk: medium
  CV Sciences, Inc. announced on November 15, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• CV Sciences Enters Material Definitive Agreement — Jul 9, 2024 Risk: medium
  CV Sciences, Inc. entered into a Material Definitive Agreement on June 3, 2024. The filing, submitted on July 9, 2024, details this agreement, which is the prim
• CV Sciences Appoints New Chief Medical Officer — Jun 25, 2024 Risk: medium
  CV Sciences, Inc. announced on June 20, 2024, the appointment of Dr. Michael L. Smith as Chief Medical Officer. Dr. Smith brings extensive experience in pharmac
• CV Sciences Files 8-K on Shareholder Votes and Financials — Jun 7, 2024 Risk: low
  CV Sciences, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 3, 2024. The fi
• CV Sciences Files 8-K: Material Agreement & Equity Sales — May 14, 2024 Risk: medium
  On May 13, 2024, CV Sciences, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also r
• CV Sciences Files 8-K on Financials — Mar 28, 2024 Risk: low
  CV Sciences, Inc. filed an 8-K on March 28, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD disclosure

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX